Three Diversified And Safe Ways To Play The Biotech Market
The adage "There's no such thing as bad press" is a lot of malarkey (to use a word favored by Vice President Joe Biden). That's especially true when it comes to the volatile biotechnology sector, which relies on the goodwill of regulators, politicians and the public. For biotech stocks, bad press is a killer.
Earlier this year, when high-profile "price gouging" scandals engulfed Valeant Pharmaceuticals and Turing Pharmaceuticals, the entire biotech sector was put in the public stockade. Turing's founder and former CEO Martin Shkreli became the reviled Snidely Whiplash of corporate America, presidential candidates vowed to punish Big Pharma and biotech investors ran for the hills.
Earlier this year, when high-profile "price gouging" scandals engulfed Valeant Pharmaceuticals and Turing Pharmaceuticals, the entire biotech sector was put in the public stockade. Turing's founder and former CEO Martin Shkreli became the reviled Snidely Whiplash of corporate America, presidential candidates vowed to punish Big Pharma and biotech investors ran for the hills.